At ESMO 2025, AstraZeneca reported that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients ...
Learn how early regulatory engagement, validated digital systems, and robust protocol design enable biotechs to run parallel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback